Related Experiment Video
Updated: Jun 15, 2026
04:11
Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
Published on: December 15, 2023
Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection
Yun-Fan Liaw1, George K K Lau, Jia-Horng Kao
1Liver Research Unit, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taipei, 105, Taiwan. liveryfl@so-net.net.tw
Digestive Diseases and Sciences
|March 19, 2010
Summary
Hepatitis B e antigen (HBeAg) seroconversion is a key goal in chronic hepatitis B (CHB) management. Achieving HBeAg seroconversion influences treatment decisions and can lead to finite antiviral therapy courses.
Area of Science:
- Hepatology and Virology
- Viral Hepatitis Research
- Clinical Infectious Diseases
Background:
- Hepatitis B virus (HBV) replication drives chronic hepatitis B (CHB) progression.
- Hepatitis B e antigen (HBeAg) status significantly impacts CHB disease course and outcomes.
- HBeAg seroconversion is a critical factor in CHB treatment guidelines, influencing therapy duration.
Purpose of the Study:
- To review and evaluate data linking HBeAg seroconversion to clinical outcomes in HBeAg-positive CHB patients.
- To assess how HBeAg seroconversion should guide patient management strategies.
- To provide expert consensus on CHB treatment in the Asia-Pacific region.
Main Methods:
- A 2-day expert meeting of leading hepatologists.
- Review of available data on HBeAg seroconversion and clinical outcomes.
- Discussion and consensus-building on patient management strategies.
Main Results:
- HBeAg seroconversion is recognized as a crucial serologic endpoint in CHB.
- Treatment selection should prioritize achieving HBeAg seroconversion.
- Specific patient profiles are outlined for pegylated interferon or nucleos(t)ide analog therapy.
Conclusions:
- HBeAg seroconversion is a significant goal in CHB management, influencing treatment choices.
- Pegylated interferon is suggested for younger HBeAg-positive patients with lower HBV DNA.
- Nucleos(t)ide analogs (entecavir, telbivudine, tenofovir) are recommended for specific patient groups and can enable finite therapy post-seroconversion.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...